| Stock Price Details |
|
Chart |
|
|
Last Price (RS)
|
2,417.25
|
|
Change (%)
|
-9.70 (-0.40%)
|
|
Best Buy (RS)
|
2417.05(x2)
|
|
Best Sell (RS)
|
2421.8(x2)
|
|
Today's Range (RS)
|
2,417.25
-
2,430.65
|
|
52-Week Range (RS)
|
2,218.00
-
3,515.95
|
|
Beta (1 Year)
|
0.57
|
|
|
|
|
|
| Index Details |
| BSE 500, BSE 200, BSE HC, BSE DOLLEX, BSE Midcap |
| News |
|
Corporate Details |
| Glaxosmithkline appoints Vinay Subramanian as Commercial Head – Oncology |
| Glaxosmithkline Pharmaceuticals consolidated net profit rises 28.60% in the December 2025 quarter |
| GlaxoSmithKline Pharmaceuticals to table results |
| Indices tumble in early trade; breadth weak |
| Glaxosmithkline Pharmaceuticals consolidated net profit rises 1.98% in the September 2025 quarter |
| Glaxosmithkline Pharmaceuticals Ltd - GlaxoSmithKline Pharmaceuticals Limited - Press Release |
| Glaxosmithkline Pharmaceuticals Ltd - GlaxoSmithKline Pharmaceuticals Limited - Outcome of Board Meeting |
| Glaxosmithkline Pharmaceuticals Ltd - GlaxoSmithKline Pharmaceuticals Limited - Investor Presentation |
| Glaxosmithkline Pharmaceuticals Ltd - GlaxoSmithKline Pharmaceuticals Limited - Outcome of Board Meeting |
| Glaxosmithkline Pharmaceuticals Ltd - GlaxoSmithKline Pharmaceuticals Limited - Analysts/Institutional Investor Meet/Con... |
|
|
|
| Incoporation Year : 1924 |
| Chairman : Renu S Karnad |
| Ownership Group : MNC Asc-Glaxo |
| Sector : MAN |
| Industry : Pharmaceuticals - Multinational |
| Registered Office |
Glaxosmithkline Pharmaceuticals Ltd
GSK House,
Dr Annie Besant Road Worli,
Mumbai,
Maharashtra-400030 |
Phone:91-022-24959595
Fax:91-022-24959494 |
| E-Mail : askus@gsk.com; ajay.a.nadkarni@gsk.com |
| URL : http://www.gsk-india.com |
|
| Investor Returns |
|
| |
Date |
Price |
Returns (%) |
| 1Week |
15-Apr-2026 |
2406.25 |
0.86 |
| 1Month |
23-Mar-2026 |
2279.85 |
6.45 |
| 3Month |
21-Jan-2026 |
2274.05 |
6.72 |
| 6Month |
21-Oct-2025 |
2762.00 |
-12.13 |
| 1Year |
21-Apr-2025 |
2815.65 |
-13.80 |
|
|
|
|
| Mutual Funds Holding |
|
| Scheme Name |
% Holding |
Market Value (Rs Cr.) |
| SBI Midcap Fund |
1.33 |
273.96 |
| Kotak Large & Midcap Fund |
0.92 |
251.13 |
| Nippon India Pharma Fund |
2.64 |
208.49 |
| Nippon India Growth Mid Cap Fund |
0.32 |
127.62 |
| SBI Dividend Yield Fund |
1.30 |
102.74 |
|
|
|
|
| Groups : Pharmaceuticals - Multinational |
|
| Company |
Last Price |
Change (%) |
52Week High |
52Week Low |
Market Cap (Rs Cr.) |
| Abbott India Ltd |
25,471.80 |
0.30 |
35,921.55 |
25,318.30 |
53,963.31 |
| Pfizer Ltd |
4,803.90 |
-0.27 |
5,987.65 |
4,123.50 |
22,037.14 |
| Astrazeneca Pharma India Ltd |
8,446.50 |
-0.09 |
10,653.05 |
7,630.00 |
21,136.00 |
| Sanofi Consumer Healthcare India Ltd |
4,625.00 |
-1.30 |
5,954.00 |
3,950.50 |
10,791.46 |
| Procter & Gamble Health Ltd |
5,075.00 |
-0.21 |
6,700.00 |
4,699.70 |
8,441.86 |
|
|
|
|